Clarivate Plc reports developments in data, analytics and workflow software for academia and government, intellectual property, and life sciences and healthcare. Its news commonly covers earnings, subscription and recurring revenue trends, cash flow and leverage actions, and progress under its operating improvement initiatives.
Company updates also focus on AI-enabled research and decision-support products, including Web of Science Research Intelligence, Nexus Connect, Cortellis Regulatory Intelligence, Derwent-based patent analytics and other Clarivate data assets. Recurring announcements address institutional research intelligence, academic library workflows, regulatory intelligence for life sciences teams, intellectual property benchmarks and investor conference appearances.
Clarivate (NYSE: CLVT) launched cash tender offers through its subsidiary to purchase up to $500 million in outstanding debt principal. Clarivate Science Holdings Corporation is offering to buy up to $400 million of its 3.875% senior secured notes due 2028 and $100 million of its 4.875% senior notes due 2029.
The 2029 notes offer pays $928.75 per $1,000 principal. The 2028 notes price will use the yield on the 4.125% U.S. Treasury due June 30, 2028, plus 50 basis points, determined at 2:00 p.m. New York City time on November 10, 2026, unless extended. Accepted notes also receive accrued unpaid interest. The offers and withdrawal rights expire at 5:00 p.m. New York City time on November 10, 2026, unless extended, with settlement expected November 13. Purchases are subject to the caps and possible proportional reductions. Neither offer requires a minimum aggregate tender or completion of the other.
Clarivate (CLVT) reported third-quarter 2026 continuing-operations revenue of $481.6 million, down year over year primarily because of disposals. Revenue fell 9.2%, while organic revenue rose 0.4% and organic recurring revenue rose 1.3%. Including discontinued operations, net loss widened to $80.8 million from $28.3 million, reflecting a $62.2 million non-cash Life Sciences & Healthcare goodwill impairment. Adjusted diluted earnings per share rose to $0.21 from $0.18.
The Life Sciences & Healthcare sale closed October 6, 2026, generating $488.4 million in net cash proceeds. Nine-month free cash flow, including discontinued operations, fell 15.6% to $233.1 million. Debt outstanding was $4,176.1 million at September 30. Clarivate expects 2026 continuing-operations revenue of $1.965 billion–$1.985 billion and adjusted EBITDA, an adjusted earnings measure, of $0.865 billion–$0.885 billion.
Clarivate (CLVT) plans to bring CompuMark trademark data and insights into Microsoft Copilot through its IPOne connector for intellectual property professionals.
IPOne is designed to let users query and analyze trademark information through natural-language requests and purpose-built AI agents within tools they already use. The platform combines Clarivate data for intellectual property research and workflows across enterprise environments. It is being developed in collaboration with corporate intellectual property teams at 15 Fortune 500 companies and law firms.
Clarivate (CLVT) announced that more than 100 institutions have adopted its Web of Science Research Intelligence platform since its launch.
The platform launched in May 2026, and adoption spans 25 countries and regions. It uses Clarivate data and academic AI to support institutional decisions on research funding, strategy and impact. Monash University moved from development partner to customer. By launch, more than 50 development partners and early adopters across 20 countries had helped shape the platform; customer engagement continues to inform its development.
Clarivate (CLVT) and Sterne Kessler announced a co-development partnership to build AI-enhanced tools for patent workflows using their respective technologies.
The collaboration combines Sterne Kessler’s practitioner-built technology and patent expertise with Clarivate’s intellectual property data and software. The partners aim to help practitioners use patent information while preserving human expertise and professional judgment. The first phase focuses on patent drafting within Clarivate’s Rowan Patents, with an initial release targeted for the first half of 2027.
Clarivate (NYSE: CLVT) completed the sale of its Life Sciences & Healthcare segment to Altaris for $600 million. The transaction was previously announced on July 6, 2026. Its remaining portfolio consists of the Academia & Government and Intellectual Property segments.
Clarivate intends to use the proceeds to reduce debt and strengthen its balance sheet. The company views the divestiture as supporting efforts to improve revenue quality and expand profitability. It will report third-quarter 2026 results on November 3, 2026 and update full-year 2026 guidance to reflect the divestiture.
Clarivate (CLVT) said its subsidiary accepted $75 million of its 2028 secured notes for purchase after a cash tender offer. Clarivate Science Holdings received $665.198 million in valid tenders against the $75 million offer cap; $825 million was outstanding before the offer. The final proration factor was 11.3%.
The offer expired on September 23, 2026, and all conditions were satisfied or waived by then. Consideration is $975.15 per $1,000 principal amount accepted. Holders of accepted notes will also receive an accrued coupon payment on the September 25 settlement date. Notes tendered but not accepted will be returned promptly.
Clarivate (CLVT) priced its subsidiary’s cash tender offer for 2028 secured notes at $975.15 per $1,000 of accepted principal.
Clarivate Science Holdings is offering to purchase up to $75 million in principal of its 3.875% senior secured notes due 2028; $825 million is outstanding. The price reflects a 4.864% reference yield determined at 2:00 p.m. New York City time on September 23, 2026, and a 50-basis-point fixed spread. Holders whose notes are accepted will also receive accrued and unpaid interest to, but excluding, the settlement date. The offer expires at 5:00 p.m. New York City time on September 23 unless extended or terminated earlier. Notes may be withdrawn until that time, subject to the offer terms. Settlement is expected September 25. Purchases remain subject to offer conditions and possible proration. The subsidiary may change or remove the purchase cap before expiration.
Clarivate (CLVT) will report its third quarter 2026 financial results before the market opens on Tuesday, November 3, 2026.
The earnings press release and supplement will be available on the Clarivate investor website at https://ir.clarivate.com. The company will host a conference call and live webcast at 8:30 AM Eastern Time the same day to review the results, and the webcast may include forward-looking information.
The live webcast is accessible via the investor relations section of the website or directly at https://events.q4inc.com/attendee/388781202. U.S. participants can join the live audio by calling 833-461-5787, and international participants can call +1 585-542-9983 using conference ID 388 781 202. A replay of the webcast will be available on the investor website about two hours after the call and will remain accessible for one year.
Clarivate (CLVT) has launched a cash tender offer for up to $75,000,000 aggregate principal amount of its subsidiary Clarivate Science Holdings Corporation's 3.875% Senior Secured Notes due 2028.
The notes have $825,000,000 aggregate principal outstanding and are identified by specified 144A and Reg S CUSIP/ISINs. The Total Consideration per $1,000 principal amount will be set using a fixed spread of 50 basis points over the yield of the 4.125% U.S. Treasury due June 30, 2028, as quoted at 2:00 p.m. New York City time on September 23, 2026, the Price Determination Date. The offer expires at 5:00 p.m. New York City time on September 23, 2026, with settlement expected on September 25, 2026, and includes payment of accrued and unpaid interest on accepted notes.